Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Dana-Farber Cancer Institute Stories

2014-04-21 13:46:28

Although doctors have long known that people with Down syndrome have a heightened risk of developing acute lymphoblastic leukemia (ALL) during childhood, they haven't been able to explain why. Now, a team of Dana-Farber Cancer Institute investigators has uncovered a connection between the two conditions. In a study posted online today by the journal Nature Genetics, the researchers track the genetic chain of events that links a chromosomal abnormality in Down syndrome to the cellular havoc...

2014-04-18 12:35:28

A Dana-Farber/Boston Children's and VA Hospital/University of South Florida team created the antiviral therapy, which harnesses the power of stapled peptide and nanoparticle technologies to thwart the respiratory virus New therapies are needed to prevent and treat respiratory syncytial virus (RSV) – a potentially lethal respiratory infection that can severely affect infants, young children and the elderly. Despite a wide range of anti-RSV efforts, there are no vaccines or drugs on the...

2014-04-07 16:05:15

Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings identify potential new targets for drug treatments. The new research could help physicians choose targeted agents with a better chance of combating pediatric high-grade astrocytomas, which are extremely difficult to...

2014-03-26 12:29:02

Comprehensive BMT(TM) will deliver an unmatched hematopoietic stem cell transplant (HSCT) data management solution for improved research and reporting SALT LAKE CITY, March 26, 2014 /PRNewswire/ -- Remedy Informatics, Inc., the leading provider of registry-based clinical informatics software for healthcare delivery and life sciences research, announced that it has been selected by the Stem Cell Transplantation program at Dana-Farber/Brigham and Women's Cancer Center to implement Comprehensive...

2014-02-04 11:57:02

Largest-ever study of 20-year survival among pediatric low-grade glioma patients highlights radiation's association with higher mortality The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults. However, children who received radiation as part of their treatment had significantly lower long-term...

2014-01-24 13:27:45

Dana-Farber Cancer Institute scientists have developed a mathematical model to predict how a patient's tumor is likely to behave and which of several possible treatments is most likely to be effective. Reporting in the journal Cell Reports, researchers combined several types of data from pre- and post-treatment biopsies of breast tumors to obtain a molecular picture of how the cancer evolved as a result of chemotherapy. "Better understanding of tumor evolution is key to improving the...

2013-12-12 10:58:07

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium. The findings offer, for the first time, a set of standard treatment guidelines for...

2013-12-09 14:08:58

Bortezomib (Velcade) reduces GVHD, boosts survival Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute. In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall...

2013-12-09 10:45:08

Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology. "This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. "Calendar age is less important than other measures,...

2013-11-19 12:29:53

Study May Help Millions Diagnosed and Treated for Cancer Each Year BOSTON, Nov. 19, 2013 /PRNewswire/ -- A group of the nation's leading cancer institutions is set to release the findings of a two-year study focused on nutrition and food preferences among patients receiving cancer treatment on Nov. 19 at Boston's TD Garden. In addition, the newly-created Cancer Nutrition Consortium will make its debut as a part of the two-day event. The group was formed to look at the issue...